Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients

Kenichiro Kinouchi, Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Kanako Murohashi-Bokuda, Hiroshi Itoh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.

Original languageEnglish
Pages (from-to)304-312
Number of pages9
JournalKidney and Blood Pressure Research
Volume33
Issue number4
DOIs
Publication statusPublished - 2010 Aug

Fingerprint

Vascular Stiffness
Ankle
Blood Vessels
Blood Pressure
Calcium Channel Blockers
Therapeutics
telmisartan
Albuminuria
LDL Cholesterol
Albumins

Keywords

  • Albuminuria
  • Arterial stiffness
  • Blood pressure
  • Cardio-ankle vascular index
  • Telmisartan

ASJC Scopus subject areas

  • Nephrology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. / Kinouchi, Kenichiro; Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Murohashi-Bokuda, Kanako; Itoh, Hiroshi.

In: Kidney and Blood Pressure Research, Vol. 33, No. 4, 08.2010, p. 304-312.

Research output: Contribution to journalArticle

Kinouchi, Kenichiro ; Ichihara, Atsuhiro ; Sakoda, Mariyo ; Kurauchi-Mito, Asako ; Murohashi-Bokuda, Kanako ; Itoh, Hiroshi. / Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. In: Kidney and Blood Pressure Research. 2010 ; Vol. 33, No. 4. pp. 304-312.
@article{2b5692ff9ffe4aacbbff08877afe11ed,
title = "Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients",
abstract = "Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.",
keywords = "Albuminuria, Arterial stiffness, Blood pressure, Cardio-ankle vascular index, Telmisartan",
author = "Kenichiro Kinouchi and Atsuhiro Ichihara and Mariyo Sakoda and Asako Kurauchi-Mito and Kanako Murohashi-Bokuda and Hiroshi Itoh",
year = "2010",
month = "8",
doi = "10.1159/000316724",
language = "English",
volume = "33",
pages = "304--312",
journal = "Kidney and Blood Pressure Research",
issn = "1420-4096",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients

AU - Kinouchi, Kenichiro

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Kurauchi-Mito, Asako

AU - Murohashi-Bokuda, Kanako

AU - Itoh, Hiroshi

PY - 2010/8

Y1 - 2010/8

N2 - Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.

AB - Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.

KW - Albuminuria

KW - Arterial stiffness

KW - Blood pressure

KW - Cardio-ankle vascular index

KW - Telmisartan

UR - http://www.scopus.com/inward/record.url?scp=77954878070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954878070&partnerID=8YFLogxK

U2 - 10.1159/000316724

DO - 10.1159/000316724

M3 - Article

VL - 33

SP - 304

EP - 312

JO - Kidney and Blood Pressure Research

JF - Kidney and Blood Pressure Research

SN - 1420-4096

IS - 4

ER -